



ADVANCE-TB

COST Action CA21164

Our journey: 2022-2026





Acknowledgements:

This booklet was compiled and designed by Raquel Villar Hernández as part of the ADVANCE-TB COST Action final activities (June and July 2026).

Thanks to all ADVANCE-TB members who contributed to the creation of this booklet and for all your support throughout these four years of the project.



**Funded by
the European Union**

This report is based upon work from COST Action ADVANCE-TB, CA21164, supported by COST (European Cooperation in Science and Technology). COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. www.cost.eu

“Over the past four years, ADVANCE-TB has brought together a committed community of researchers, clinicians, and stakeholders united by a common goal: to advance knowledge, innovation, and collaboration in the fight against tuberculosis.

This booklet celebrates not only the scientific achievements and milestones reached throughout the project, but also the people behind them. Through shared expertise, interdisciplinary exchange, and a spirit of cooperation, ADVANCE-TB has fostered new ideas and projects, strengthened international networks, and supported the development of the next generation of scientists.

Within these pages, you will find key data, memorable moments, and personal reflections from those who have contributed to the success of the initiative. Together, they tell the story of a project that has gone beyond its objectives—building lasting connections and laying the groundwork for future progress in tuberculosis research.

It has been a real pleasure to lead this initiative, and I am truly proud of what we have achieved together. As ADVANCE-TB comes to an end, we look forward with confidence, knowing that the impact of this collective effort will continue to resonate in the years to come.”



Alicia Lacoma
Action's Chair

ADVANCE-TB

Towards an improvement in diagnostics and treatment strategies for tuberculosis control

Launched on September 2022, ADVANCE-TB COST Action (CA21164) aimed to **address the complexity of tuberculosis (TB) management.**

ADVANCE-TB is a research network that offers opportunities for collaboration between clinicians, academic researchers from interdisciplinary backgrounds, industry and non-governmental organizations with the **aim of advancing TB research.**



The Action focused on:



Developing best clinical practices & experimental standardization protocols.




Stimulating the development & optimization of products for diagnostic, treatment, & monitoring purposes.



Disseminating knowledge & allowing capacity-building.

Within ADVANCE-TB we had different **working groups (WG)** covering the different purposes of the Action:



We started with:



15 Hospitals/Clinics
71 Universities
44 Research Institutes



7 SMEs



1 NGO

ADVANCE-TB leaders

Throughout the life of the Action.



Alicia Lacoma
Action's Chair



Sven Hoffner
Action's Vice-Chair



Tânia Silva
Action's Vice-Chair



**Andrii
Dudnyk**



**Zorica
Nanovic**



**Margarida
Saraiva**



**Anda
Viksna**

WG1 leaders

WG2 leaders



**Olena
Rzhepishevskya**



**Traian
Panciu**



**Martina Hrast
Rambaher**

WG3 leaders



**Mateja Janković
Makek**



**Raquel Villar
Hernández**

Science communication
coordinators and WG4 leaders



**Cristina Prat
Aymerich**

Grant awarding
coordinator



**Oxana
Zinchenko**
Grants evaluation
committee



**José
Domínguez**
Grant holder scientific
representative



**Melanie
Giorgi**
Grant holder
manager



**Sandra
Fernández**
Senior international
project manager

What have we done in
these 4 years?

Working Group 1



Main goals

1. To establish a clinical study platform for performing multi-centre high-quality clinical studies in the field of TB. A collaboration agreement is being drafted and network of potential participant (academic clinical sites) identified across the members of ADVANCE-TB. This is coupled with a database of epidemiological, clinical, radiological and microbiological variables in RedCap, managed by IGTP.
2. To Report on TB management in the different countries participating in the ADVANCE-TB Action. Two initiatives have arisen and are ongoing:
 - To prepare a report on the current Infection Prevention Control (IPC) measures within ADVANCE-TB clinical sites. This activity started with exchanging experiences and hands-on workshop held by StopTB Partnership during the WG1 meeting in Sofia (24-25 March 2026).
 - To elaborate a document on TB control in migrants in the Balkan countries: the partners and country representatives have been identified, forming a working group, and draft of Consensus Document has been prepared. The cooperation with International Organisation for Migration (IOM) has also been enroled in this activity.



Dissemination and outputs

Members of WG1 have participated in establishing a clinical study platform for performing multi-centre high-quality clinical studies in the field of TB, preparing different manuscripts (see pages 20 to 22), and organizing the Workshop on *Harmonizing procedures for clinical studies in TB*, celebrated in Sigmaringen (Germany) on September 2025.

Message from Zorica Nanovic (WG1 leader)

“ The ADVANCE-TB CA21164 Cost Action is a practical indicator of how one dream and opportunity can be turned into many potential opportunities, and how a no-fancy and pharmaco-unattractive disease can be elevated to an enviable level and given the dimension it deserves. ADVANCE-TB networking is a motivational lever - how to go further and forward - because it opens up new horizons of cooperation and dissemination of knowledge in the field of tuberculosis. I think that with ADVANCE-TB a serious global scientific network of collaborators has already been established, which will further sustainably support and participate in tuberculosis related research. ”



Skopje, February 2023

Working Group 2



Main goals

1. To uncover novel TB biomarkers based on host-pathogen interactions.
2. To develop novel technological platforms for diagnostic purposes.
3. To evaluate current and design novel molecular tests.



Dissemination and outputs

The collaborative efforts of WG2 have resulted in the elaboration of several manuscripts (see pages 20 and 21). In February 2026, Margarida Saraiva led the Workshop *From bench to bedside: how does this actually work?* in Porto (Portugal).



Porto, February 2026

Message from Margarida Saraiva (WG2 leader)

“ WG2 is very diverse and includes a large number of people, and thus challenging to coordinate. Overall, I think this WG was very active during ADVANCE-TB, with several collaborative initiatives leading to different outputs, including successful grant applications. Personally, coordinating WG2 allowed me to step out of my comfort zone by contacting with clinical practice and research in a deeper way, opening my horizons and promoting my involvement in research collaborations that were not possible before. All this really summarizes the purpose of COST Actions. ”

Working Group 3



Main goals

1. To establish a unique database of compounds/drugs identified and developed by members of the Action. This was coordinated by Tânia Silva and represents an important step toward drug discovery efforts.
2. To define pre-clinical and clinical protocols for the validation of new drugs (particularly relevant for host-directed therapies, anti virulence drugs and drug delivery systems). The work is led by Martina Hrast and it is almost finished.
3. To monitor selected biomarkers during TB treatment. This was led by Irene Latorre.



Dissemination and outputs

The collaborative efforts of WG3 have resulted in the compound/drugs with antimycobacterial activity database and several manuscripts (see pages 20 and 21). In April 2025, WG3 organized a workshop in Krakow (Poland), and many members used STSMs to visit other laboratories where they gained new knowledge and expertise.

Message from Martina Hrast (WG3 leader)

“ The COST Actions are great initiative to meet new people, establish new connections, discover what you can do together with other researchers and to broaden the knowledge on specific topics. Although coordinating a large and diverse group of researchers is challenging, WG3 successfully worked together on review papers, protocol development, and grant applications. The collaboration in COST actions strongly demonstrated how collaborative networks can accelerate scientific progress and create opportunities well beyond the lifetime of the Action. ”



Krakow, April 2025

Working Group 4



Main goals


1. Create the science communication plan.
2. Create a website and social media accounts to publish information on the Action's achievements and announcements.
3. Engage new researchers, other reference networks and private partners.

4. Promote the Action and raise public awareness through our communication channels and website.
5. Publish the WGs' results.



Dissemination and outputs

During these four years, we managed to cover the main goals and also engage in further initiatives. Briefly:

- Science communication plan.
 - Visual identity and guidelines.
 - Website: www.advance.tb.eu
- 
- Especially active on LinkedIn: regular updates and announcements (more than 60 posts per year) and more than 890 followers.
 - Three social media channels: LinkedIn, Facebook and X.
 - Press release about our Action, done together with Karima BenSalah from the COST communication team (November 2023): *Promising steps towards improving tuberculosis diagnostics and treatment.*
 - Organization of a two-day *Workshop on Effective Communication*. Led by Raquel Villar Hernández in Brussels (Belgium) on March 2026. Had 15 speakers, ADVANCE-TB members and non-members. Had 54 attendees in total from all WGs.
 - Two awareness campaigns per year: World TB Day (March 24th) and International Day of Women and Girls in Science (February 11th).
 - Ongoing interaction with our grantees and sharing their experiences.
 - Mateja Janković Makek and Raquel Villar shared our Action and the communication activities done in two events organized by COST.

- Part of the COST report *Best practice examples: COST Actions supporting Young Researchers and Innovators* (May 2026) featuring some of our grantees and their experiences, and some of our initiatives to support young researchers.

Message from Mateja Janković Makek and Raquel Villar Hernández (WG4 leaders)

“Coordinating the communication working group within ADVANCE-TB has been a very rewarding experience for both of us. Although our primary professional roles are mainly focused on clinical practice and science, this experience highlighted even more strongly the importance of communication in sharing knowledge, increasing visibility, and strengthening the TB research community. Over the past four years, we have learned a great deal and gained valuable new perspectives, while contributing to dissemination activities, and deepening our understanding of the importance and value of multidisciplinary collaboration within COST Actions. We would like to sincerely thank all WG4 and ADVANCE-TB members who participated in our communication activities and contributed to raising awareness about TB.”



Brussels, March 2025

Publications and manuscripts



Reviews and consensus documents accepted

- *The study of immunological markers in tuberculosis across animal models and its translation to human research*. Lab Animal 2026. Led by Irene Latorre. Accepted for publication <https://pubmed.ncbi.nlm.nih.gov/42243511/> **WG2**
- *Advancing therapies for mycobacterial diseases: from small molecules to host-directed strategies*. Led by Tânia Silva and Mafalda Sarraguça. Medicinal Research Reviews 2025. **WG3**

Reviews and consensus documents submitted

- *Repurposing drugs for tuberculosis and pulmonary nontuberculous mycobacteria: economics, current progress and future directions*. Led by Milka Hammarén. Clinical Microbiology Reviews 2025 (rejected). New submission in preparation. **WG3**
- *Strengthening Tuberculosis Clinical Trials: Operational Recommendations and Consensus Statement from the SMA-TB and ADVANCE-TB Consortia using a Delphi Method*. Led by Cristina Vilaplana and Alicia Lacoma. BMJ Global Health 2026 (rejected). BMJ Public Health 2026. **Submitted. WG1 & WG2**

Reviews in preparation

- *Mycobacterium tuberculosis: A Comprehensive Review of Smart Theranostic Approaches for Diagnosis and Therapy*. Led by Jagriti Narang. Writing process complete, but further refinement is needed to improve consistency and overall quality. **WG2**
- *Drug delivery approaches for the treatment of TB and NTM infections*. Led by Mafalda Sarraguça and Pinar Cakir Hatir. Sections scheme identified and contributor selection pending. **WG3**
- *Computer-Aided Detection (CAD) for Tuberculosis*. Led by Maria Jesus Ledesma and Daniel Capellán. Sections scheme identified. **WG1 & WG2**

Other manuscripts in preparation

- *Protocols for phenotypic antimicrobial resistance testing: advantages and limitations.* Led by Martina Hrast. Data extraction from papers shared among members. First draft document. **WG3**
- *Consensus Document: “TB control in migrants in the Balkan Countries”.* Led by Zorica Nanovic, Jose Domínguez and Alicia Lacoma. Sections scheme identified and contributor selection pending. **WG1**

Published manuscripts with ADVANCE-TB members listed as authors/ Acknowledgments

- *Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.* Domínguez J, Boeree MJ, Cambau E, et al. TBnet and RESIST-TB networks. Lancet Infect Dis. 2023 Apr;23(4):e122-e137. <https://pubmed.ncbi.nlm.nih.gov/36868253/> **WG1 & WG2**
- *Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine.* Dudnyk A, Hempel M, Lytvyniuk O, et al. Therapeutic Advances in Respiratory Disease. 2024 May;18:17534666241249841. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11143817/> **WG1 & WG2**
- *A multinational Delphi consensus on tuberculosis screening of migrants in Europe.* Pinheiro M, Aguiar A, Moreira DN, et al. ERJ open research. 2025 Nov;11(6):00574-2025. Led by Prof. R. Duarte. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12720149/> **WG1**
- *Multi-view deep learning framework for the detection of chest X-rays compatible with pediatric pulmonary tuberculosis.* Capellán-Martín D, Gómez-Valverde JJ, Sánchez-Jacob R, et al. Nat Commun. 2025 Oct 27;16(1):9170. <https://pubmed.ncbi.nlm.nih.gov/41145423/> **WG1 & WG2**

- *Mental health management in the context of TB care in the WHO European Region: a consensus statement*. Vilaplana C, Konstantynovska O, Rzhapishevska O, et al. *IJTLD Open*. 2026 May 11;3(5):275-285. doi: 10.5588/ijtldopen.25.0661. <https://journals.theunion.org/content/ijtldo/3/5/275> **WG1**

Collaborations beyond the Action




The network established through this COST Action has facilitated several collaborative grant applications:


- **Study of first and second-line drug resistance patterns of *Mycobacterium tuberculosis* by molecular methods in clinical samples for preparedness of TB control healthcare system in Ukraine (TBpreparedness4Ukraine)**. Led by A. Dudynk (IGTP). Members from 5 different institutions. Funding entity: MSCA4Ukraine/Alexander von Humboldt Foundation 2023. **Granted. WG1-WG2**
- **A step forward for unraveling the immune mechanisms and tools for tuberculosis spectrum management (TB-SPECTRUM)**. Led by I. Latorre (IGTP). Members from 8 different institutions. Funding entity: Horizon Europe MSCA Staff Exchanges 2025. **Granted. WG1-WG2**
- **RE-THINK-TB uses nanomedicine (THEDES in LNPs) and omics analysis to construct a AI-guided Cellular Response Model, enabling the accelerated design of a safer, resistance-resilient TB cure**. Led by M. Sarraguça (University Porto). Members from 2 different institutions. Funding entity: La Caixa Research Foundation 2026. **Not granted. WG3**
- **Advancing prevention, treatment and rehabilitation of post TB lung disease through innovative approaches that reveal key mechanisms and identify diagnostic, progression and treatment response markers (AFTER-TB)**. Led by J. Domínguez (IGTP). Members from 9 different institutions. Funding entity: Horizon Europe 2026. **Submitted. WG1-WG2**

- **Immunodiagnostic of non-tuberculous mycobacteria infection and the use of the NTM-iSpot.** Led by R. Preyer (GenID). Members from 3 different institutions. Funding entity: German Federal Ministry of Research, Technology and Space. **Granted. WG2**
- **AccelMab: Accelerating *Mycobacterium abscessus* drug discovery.** Led by S. Gomes (i3S). Members from 2 different institutions. Funding entity: ESCMID Study group Collaboration Grant. **Not granted. WG3**
- **Optimizing multi-drug therapies for tuberculosis (OPTIM-TB).** Led by A. Lacoma (IGTP). Members from 6 different institutions. Funding entity: OH-AMR Call 2026. **Not granted. WG3**
- **Activating Innate Killing to Improve Combination Treatment of Resistant Pulmonary Infections (ComPI).** Led by M. Burnet (Synovo). Members from 3 different institutions. Funding entity: Horizon Europe 2026. **Not granted. WG3**
- **How to prevent and early manage post-TB conditions (HOPE).** Led by C. Vilaplana (IGTP). Members from 10 different institutions. Funding entity: Horizon Health 2023. **Not granted. WG1**
- **Transmission of *Mycobacterium tuberculosis* Strains in Bulgaria and the Balkans, with a Focus on Pediatric Patients.** Led by V. Valcheva (SAIM). Members from 5 different institutions. Funding entity: Bulgarian National Science Fund, Competition for financial support of basic research projects – 2025. **Granted. WG1-WG2**

ADVANCE-TB in numbers



14 members with
leadership positions
(throughout the life of the Action)




● Young researchers (43%)
● Female (71%)

120k€


invested in
grants




Number of grants
awarded by
grant type




**Events
per type**



Events per GP



**Our growth on
LinkedIn**



**Web sessions by
country**



GP: Grant Period. ITC: Inclusiveness Target Country. SME: Small and medium enterprise. STSM: Short-Term Scientific Mission. WG: Working Group. YRI: Young Researcher and Innovator.

As this journey comes to an end, we invited our members to share how ADVANCE-TB shaped their professional work and/or career and which benefits would they highlight of being part of this COST Action.

Here is what they said.

ADVANCE-TB has been crucial for my scientific growth. It allowed me to expand my collaborations and gain visibility in the field of mycobacteria. As a young researcher, being part of this international community has been very rewarding in terms of my professional growth.

For me, there were many benefits to being part of ADVANCE-TB. I had the amazing opportunity of becoming Vice-Chair of this COST Action, which improved my management skills and increased my visibility in the field. Through ADVANCE-TB I had the opportunity to establish multiple international collaborations, supervise students on secondment in my lab, coordinate manuscript reviews, submit international research proposals, and attend international scientific meetings that would have been impossible without ADVANCE-TB funding.

Tânia Silva
i3S, Portugal

ADVANCE-TB was important to connect me and my research group with colleagues working in TB in the EU, particular with clinical partners.

Margarida Saraiva
i3s, University of Porto, Portugal

An important achievement was to visit clinics and research institutions, academic and non-academic, in different countries, to see how they are organized and function, what are they current activities and research topics.

Elmira Ibraim
Institutul de Pneumoftiziologie Marius Nasta, Romania

Meetings and lectures improved my knowledge. As benefits I would highlight, building connections with colleagues worldwide.

Artemii Bogomolov
Pirogov National Medical University, Ukraine

ADVANCE TB helped me gain insight in different aspects of Tuberculosis management, stepping outside the clinical part and going more and more in to the fundamental research. I had the chance to meet people that are highly professional in their work in Tuberculosis diagnostic and treatment, and work strongly in decreasing TB burden worldwide.

Traian Constantin Panciu
Marius Nasta Institute, Romania

It has been really interesting the networking and to get to know ongoing research on mycobacterial diseases from many different perspectives. As benefit of being part of this Action, I would say the interdisciplinary networking that fosters creative collaborations.

Cristina Prat Aymerich
ECRAID, The Netherlands

It strengthened my interdisciplinary collaborations and expanded my work on nanomaterials for TB diagnosis and drug delivery. I also contributed by organizing a training school and participating in an STSM.

ADVANCE-TB helped me build strong collaborations and move my research closer to real biomedical applications.

Pinar Cakir Hatir
Istinye University, Turkey

I had an opportunity to meet people interested in the same area of work, share knowledge and experience. Also, I had the opportunity to participate in the project management structures and learn a lot about leadership roles. As benefits of being part of this COST Action I highlight meeting people, participating in leadership, learning, and growth.

Mateja Janković Makek
University Hospital Center Zagreb, Croatia

Apart from participating in final meetings and other activities, thanks to the network I was able to carry out two short-term missions that were very meaningful for my thesis. The most important benefit is the opportunity to connect with researchers from other countries and learn how they work. This exposure has broadened my perspective and enriched my professional development.

Júlia Valera Paloma
Hospital Universitari Germans Trias i Pujol, Spain

This action contributed to my connection with scientists across Europe, with whom I shared information that I probably wouldn't have if I hadn't been part of it (conferences, invited lectures, webinars).

Zrinka Puharić
Bjelovar University of Applied Sciences (BUAS), Croatia

ADVANCE-TB created a supportive and inspiring scientific community that helped shape my research perspective and strengthened my motivation to continue working in tuberculosis research. One of the main benefits of being part of ADVANCE-TB was the opportunity to engage in a highly collaborative and interdisciplinary scientific community dedicated to advancing tuberculosis research from different perspectives. The Action created an environment where researchers from diverse fields could openly exchange ideas, share expertise, and establish meaningful collaborations.

Mafalda Sarraçuça

LAQV-REQUIMTE, Faculty of Pharmacy, University of Porto, Portugal

The network served as a vital platform for knowledge exchange, enabling me to harmonize my local methodologies with international best practices. Through the ADVANCE-TB network, I've been able to build strong professional partnerships that I'm confident will evolve into productive, long-term collaborations for our team.

Violeta Ruseva

Stephan Angeloff Institute of
Microbiology, Bulgarian Academy of
Sciences, Bulgaria

Being part of ADVANCE-TB expanded the scope of my perspectives regarding research in TB. The benefits I would highlight are: possibilities for new interactions, support to make visible and communicate my research, funding to start the incorporation of new researchers in my team.

Dario García de Viedma

Hospital Gregorio Marañón, Instituto
de Investigación Sanitaria Gregorio
Marañón, CIBERES, Spain

ADVANCE-TB has significantly increased my capacity and sharpened my skills in tuberculosis research, enhanced my understanding of innovative TB diagnostic and case-finding approaches, improved my project management and scientific communication skills, and expanded my professional network within the TB research community. Through the project, I have gained valuable experience in research coordination, data management, and multidisciplinary collaboration across different institutions and countries.

James Ngbede Ekwu

Zankli Research Centre, Bingham University, Nigeria

ADVANCE-TB has significantly contributed to my professional development by strengthening my involvement in international and interdisciplinary collaboration in tuberculosis research. Through the network, I have expanded my scientific connections, actively participated in meetings and exchanges, and gained exposure to diverse methodological approaches, including both epidemiological and laboratory perspectives. Importantly, it has helped me to refine my research direction towards more translational work and to engage in new collaborative initiatives. The experience has also supported my career progression by providing opportunities for mobility, knowledge exchange, and the development of competitive research proposals.

It was for me a very fruitful scientific journey.

Eka Kokhreidze
European University, Georgia

Being part of ADVANCE-TB has been a very rewarding experience, both scientifically and personally. I really liked the multidisciplinary nature of the network, bringing together experts from different fields to advance TB research, as well as the many opportunities for collaboration and networking through meetings and workshops. I am also very grateful for the opportunity to be part of the Core Group and enjoyed engaging with inspiring colleagues across Europe. A particular highlight for me was organizing a workshop on effective communication, with its inspiring participants and engaging atmosphere.

Raquel Villar Hernández
GenID GmbH, Germany

Coordinating my first European-funded project has been both a challenge and a truly rewarding experience. It required a great deal of dedication, but it also gave me the opportunity to grow professionally and personally. I am proud of what we achieved as a team, and I especially value everything I have learned along the way.


Alicia Lacom
IGTP, Spain



My journey with ADVANCE-TB began with an invitation to participate, continued through membership in the Management Committee and the Core Group, and finished with the leadership of Working Group 1 (Clinical Cohorts of Patients). Approaching its closing, I can say that the four-year work in the project have been one of the most important professional, scientific and research experiences of my career. It is more than certain that the challenge of bringing together professionals with different affiliations and professional backgrounds, some more and some less financially, scientifically, institutionally and infrastructurally powerful, but ready for new ideas merged in a unified approach of collaboration and joint scientific and research projects, complementary and specific activities - resulted in the establishment of a wide network of collaborators across and beyond Europe. Representatives from different universities, hospitals and laboratories, through meetings and workshops, and with an emphasis on mobility and secondment, had the opportunity to personally meet and exchange experiences, to apply and participate in international projects and leave an open horizon for the future. It was an honor to be part of this comprehensive project, which reflects togetherness and complementarity, as well as respect for every contribution to cooperation in the field of tuberculosis.



Zorica Nanovic




Institute for Lung Diseases and Tuberculosis, Skopje, North Macedonia
Goce Delcev University, North Macedonia

*More and complete statements can be
found on our website.*









Over the past four years, this COST Action has brought together researchers and collaborators from different countries, disciplines, and backgrounds in a shared spirit of cooperation, discovery and improvement.

We sincerely thank all participants, working group leaders, contributors, and partners for their dedication, enthusiasm, and valuable contributions throughout this journey.

We also gratefully acknowledge the support and funding provided by European Cooperation in Science and Technology (COST), whose commitment to fostering international collaboration made this network and its activities possible.

The experiences, ideas, and relationships created through this Action will continue well beyond the project itself.

Thank you!



ADVANCE-TB 2026